NEW YORK (GenomeWeb) – Guardant Health announced today that it has created separate partnerships with AstraZeneca, Merck, Merck KGaA, and Pfizer to develop a new 500-plus-gene liquid biopsy panel for use in clinical trials and cancer drug and immunotherapy development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.